– Prohibition Partners
Conor O’Brien, Prohibition Partners
In order to best serve the medical cannabis patient population in Europe, operators require a knowledge of who the patients are and why they rely on those medicines. Prohibition Partners has summarised the accessible data under, and supplied more research in our current European Cannabis Report.
Prohibition Partners has gathered data for European clinical cannabis patients from federal government agencies and individual research groups to research high-level statistics on patients being prescribed medical cannabis. One of the most important sources of data within Europe is currently Project Twenty21, run by Drug Science in the united kingdom, which will be a patient registry which’aims to make the UK’s largest body of evidence to its effectiveness and tolerability of health cannabis’ by facilitating patient access and then publishing anonymised data.
Prohibition Partners spoke to Dr Anne Katrin Schlag, head of research in Drug Science, regarding the data ahead of an upcoming publication on UK patients at the Journal of Psychopharmacology. She clarified that:
‘Our patient population includes a massive age range (less or more by 18–80 years old). Their consistently substantial levels of comorbidity and very low quality of life demonstrate exactly how unwell many of them are. Therefore, some stereotypes of herbal cannabis users like being 20-something, wholesome recreational users looking for a legal source could not be further from the truth.’ .
Drug Science also supplied some updated info on the united kingdom for the research below.
Medical cannabis demonstrates promise in handling a broad range of conditions, being a modulator of the endocannabinoid system, also using a safe and powerful anti-inflammatory profile. While cannabinoid medications are accepted for a restricted set of states, such as Epidiolex for infrequent epilepsies, patients and physicians make use of these medicines to cover many more conditions.
Producers of medical cannabis in the European economy ought to pay attention to the conditions that cannabis is being prescribed around the continent. The requirements of patients vary widely by illness, such as where CBD/Epidiolex® is more useful for epileptic patients, THC is much more useful for the decrease in nausea. Below are the signs for which medical cannabis goods are prescribed per country.
Pain is absolutely the most commonly cited reason for doctors to prescribe medical cannabis. Chronic pain affects as many as 1 in 3 individuals in developed countries, commonly defined as pain occurring most days or daily for six months. European trends are comparable with North America in medical cannabis being prescribed most frequently for pain. This is also true in the United Kingdom according to data supplied by Dr Anne Katrin Schlag:
‘Anxiety and stress disorders were the two most common ailments in both women and men; girls were more likely to report that a main condition of chronic illness (61.5percent versus 51.0percent ) while men were more likely to report stress disorders (38.0% vs 23.8percent ).’
Medical cannabis patients trying to treat pain differ in their need depending on seriousness of pain and frequency of use. Generally speaking, patients having pain prefer cannabinoid drugs with high and balanced quantities of THC and CBD, with high end consumers preferring top THC and reduced CBD. This is represented by the sorts of health cannabis currently available in Europe, with the majority of countries having a wider collection of medications with higher THC and balanced THC:CBD than high CBD alone.
The typical age of medical cannabis patients in Europe is comparable to that of the North American patient population, if slightly older. In the most significant market in Europe, Germany; the age of medical cannabis users in the country is 54. Denmark and Italy are notable for having an population of mature medical cannabis patients in an average of 57 and 58 respectively. Early data from Job Twenty21 indicates that the patient collections in the united kingdom are somewhat younger compared to other European countries, with an average age of around 39.
Individuals of different age classes are known to prefer distinct medical cannabis products. By way of instance, data in the official poll of German patients indicate that the typical quantity of medical cannabis patients using flowers is 46, although the average for extract use is 57. The Federal Institute for Drugs and Medical Devices (BfArM) in Germany has noticed that lots of prescriptions for cannabis flower go unreported, which could skew the data because these patients have been known to be often male and marginally younger than patients utilizing other goods.
The data on gender of medical cannabis patients in Europe indicate that the equilibrium is more between male and female compared to North America, where the patient population is majority male. In the Netherlands and Germany, the gender split isn’t large. Denmark and Italy are noteworthy for their patient populations having a large female majority in 62% and 63% respectively. Based on data in Job Twenty21, the UK’s patient population is more akin to that in North America concerning gender balance, with a 66 percent majority being man as of April this year. Germany and the UK are the only countries for which data to non-binary patients have been accessible and to date around 0.1% and 0.6percent of patients identify as such in each country.
Much like demographics, gender plays a part in patient product decision. In Germany for instance, 68 percent of patients getting flower are male, whereas females dominate the use of dronabinol (58%), Sativex® (54 percent ) and extracts (54 percent ), as reported in the polls of the BfArM.
The data presented here reflects a lot of the available data on patients in Europe. It should be said that the data represent a small portion of the entire patient population in the world, with millions of individuals nevertheless self-prescribing medical cannabis and huge swathes of patients not being contained in published data, such as the inhabitants in Switzerland. Because these data become available, Prohibition Partners will provide relevant updates as part of continuing efforts to support patient demands being fulfilled in Europe.
Prohibition Partners dive deeper in this and other topics within their recently released European Cannabis Report: 6th Edition that appears at social, economic, regulatory and health trends including:
- The progress of medical cannabis gain in Europe
- The progress of adult-use initiatives
- The introduction of European capital markets into cannabis
- The impact of COVID-19 on patient access and the industry at high
- The patients in Europe and the goods They’re utilizing
- The trends in product formula between extracts and isolates
- The diversification of the supply chain in Europe
For bespoke research and consulting and sponsorship opportunities, contact: email@example.com